Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968644 | 1.00 | DPP4 (0.73) | DPP4OPRM1OPRK1CYP3A4 | |
| SCHEMBL386746 | 0.87 | DPP4 (0.92) | DPP4OPRM1OPRK1 | |
| SCHEMBL386747 | 0.87 | DPP4 (0.92) | DPP4OPRM1OPRK1 | |
| SCHEMBL28890829 | 0.84 | DPP4 (0.85) | DPP4OPRM1OPRK1 | |
| Alogliptin SCHEMBL29352995 | 0.84 | DPP4 (1.00) | DPP4OPRM1OPRK1 | |
| Alogliptin SCHEMBL121028 | 0.84 | DPP4 (1.00) | DPP4OPRM1OPRK1 | |
| Alogliptin SCHEMBL17036596 | 0.84 | DPP4 (1.00) | DPP4OPRM1OPRK1 | |
| Alogliptin SCHEMBL174188 | 0.84 | DPP4 (1.00) | DPP4OPRM1OPRK1 | |
| SCHEMBL8429011 | 0.84 | DPP4 (0.72) | DPP4OPRM1OPRK1 | |
| SCHEMBL5968476 | 0.84 | DPP4 (0.72) | DPP4OPRM1OPRK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697342-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2006-09-06 | — | — | EP | claimed |
| WO-2005030751-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-07 | — | — | WO | claimed |
| US-20050065144-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | claimed |
| EP-1697342-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005030751-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-07 | — | — | WO | disclosed |
| US-20050065144-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050065144-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050065144-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065144-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885OPRM1 1717/4885OPRK1 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.